Search Results | Blood | American Society of Hematology

1-20 of 225

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

DOI: https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

DOI: https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

DOI: https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

DOI: https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

DOI: https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Francesca Del Bufalo, MD, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Ignazio Caruana, PhD, Matilde Sinibaldi, PhD, Luciana Vinti, MD, Pietro Merli, MD, Mattia Algeri, MD, Annalisa Ruggeri, MD, Federica Galaverna, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Giovanna Leone, MD, Valentina Bertaina, PhD, Franca Fassio, PhD, Monica Gunetti, PhD, Stefano Iacovelli, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 1341.

DOI: https://doi.org/10.1182/blood-2019-129821

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

DOI: https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

DOI: https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

DOI: https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

DOI: https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

DOI: https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

DOI: https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

DOI: https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD

Blood (2019) 134 (Supplement_1): 778.

DOI: https://doi.org/10.1182/blood-2019-128255

Published: 2019

Journal Articles

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Simone Critchlow, Miranda Cooper, Ilse van Oostrum, Verna L Welch, PhD MPH, T. Alexander Russell-Smith

Blood (2019) 134 (Supplement_1): 3427.

DOI: https://doi.org/10.1182/blood-2019-123454

Published: 2019

Journal Articles

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Pinaki P Banerjee, PhD, Christina Ganesh, BSN, RN, Mecit Kaplan, MS, Vandana Nandivada, BS, MS, Ana Karen Nunez Cortes, MD, Amin M. Alousi, MD, David Marin, MD, Elizabeth J. Shpall, MD, Rohtesh Mehta, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Katayoun Rezvani, MD PhD

Blood (2019) 134 (Supplement_1): 1298.

DOI: https://doi.org/10.1182/blood-2019-125931

Published: 2019

Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 1299.

DOI: https://doi.org/10.1182/blood-2019-130283

Published: 2019

Journal Articles

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Shaun Fleming, MBBS,, Nicola Venn, BSc, John Reynolds, PhD, Uyen Nguyen, John Kwan, MBBS,FRACP,FRCPA, John Moore, MDFRACP,FRCPA, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Matthew Greenwood, MBBS, FRACP, FRCPA, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Ashish Bajel, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Rosemary Sutton, BSc MSc PhD

Blood (2019) 134 (Supplement_1): 1300.

DOI: https://doi.org/10.1182/blood-2019-132048

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Blood (2019) 134 (Supplement_1): 1302.

DOI: https://doi.org/10.1182/blood-2019-124882

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

DOI: https://doi.org/10.1182/blood-2019-124254

Published: 2019

NARROW

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

DARTs point the way forward in AML

Blinatumomab for infant acute lymphoblastic leukemia

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only